101 related articles for article (PubMed ID: 30217414)
1. Discovery of DS42450411 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4-aminopyrimidine derivatives.
Fukuda T; Ishiyama T; Katagiri T; Ueda K; Muramatsu S; Hashimoto M; Aki A; Baba D; Watanabe K; Tanaka N
Bioorg Med Chem Lett; 2018 Nov; 28(20):3333-3337. PubMed ID: 30217414
[TBL] [Abstract][Full Text] [Related]
2. Discovery of DS28120313 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4,6-disubstituted indazole derivatives.
Fukuda T; Goto R; Kiho T; Ueda K; Muramatsu S; Hashimoto M; Aki A; Watanabe K; Tanaka N
Bioorg Med Chem Lett; 2017 Dec; 27(23):5252-5257. PubMed ID: 29079471
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and SAR studies of 3,6-disubstituted indazole derivatives as potent hepcidin production inhibitors.
Fukuda T; Ueda K; Ishiyama T; Goto R; Muramatsu S; Hashimoto M; Watanabe K; Tanaka N
Bioorg Med Chem Lett; 2017 May; 27(10):2148-2152. PubMed ID: 28377056
[TBL] [Abstract][Full Text] [Related]
4. Discovery of DS79182026: A potent orally active hepcidin production inhibitor.
Fukuda T; Goto R; Kiho T; Ueda K; Muramatsu S; Hashimoto M; Aki A; Watanabe K; Tanaka N
Bioorg Med Chem Lett; 2017 Aug; 27(16):3716-3722. PubMed ID: 28705644
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibition of prolyl hydroxylase protects against inflammation-induced anemia via efficient erythropoiesis and hepcidin downregulation.
Jain M; Joharapurkar A; Patel V; Kshirsagar S; Sutariya B; Patel M; Patel H; Patel PR
Eur J Pharmacol; 2019 Jan; 843():113-120. PubMed ID: 30458168
[TBL] [Abstract][Full Text] [Related]
6. Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties.
Mathieu S; Gradl SN; Ren L; Wen Z; Aliagas I; Gunzner-Toste J; Lee W; Pulk R; Zhao G; Alicke B; Boggs JW; Buckmelter AJ; Choo EF; Dinkel V; Gloor SL; Gould SE; Hansen JD; Hastings G; Hatzivassiliou G; Laird ER; Moreno D; Ran Y; Voegtli WC; Wenglowsky S; Grina J; Rudolph J
J Med Chem; 2012 Mar; 55(6):2869-81. PubMed ID: 22335519
[TBL] [Abstract][Full Text] [Related]
7. Target identification of hepcidin production inhibitors by a combination of chemical proteomics and radioactive compound binding assay.
Sasaki M; Ueda K; Fukuda T; Tanaka N; Shimizu H; Kubota K
Biochem Biophys Res Commun; 2018 Sep; 503(4):2878-2884. PubMed ID: 30139518
[TBL] [Abstract][Full Text] [Related]
8. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin.
Nemeth E; Rivera S; Gabayan V; Keller C; Taudorf S; Pedersen BK; Ganz T
J Clin Invest; 2004 May; 113(9):1271-6. PubMed ID: 15124018
[TBL] [Abstract][Full Text] [Related]
9. Treatment with anti-IL-6 receptor antibody prevented increase in serum hepcidin levels and improved anemia in mice inoculated with IL-6-producing lung carcinoma cells.
Noguchi-Sasaki M; Sasaki Y; Shimonaka Y; Mori K; Fujimoto-Ouchi K
BMC Cancer; 2016 Apr; 16():270. PubMed ID: 27068103
[TBL] [Abstract][Full Text] [Related]
10. Hepcidin Mitigates Renal Ischemia-Reperfusion Injury by Modulating Systemic Iron Homeostasis.
Scindia Y; Dey P; Thirunagari A; Liping H; Rosin DL; Floris M; Okusa MD; Swaminathan S
J Am Soc Nephrol; 2015 Nov; 26(11):2800-14. PubMed ID: 25788528
[TBL] [Abstract][Full Text] [Related]
11. Pentosan polysulfate to control hepcidin expression in vitro and in vivo.
Asperti M; Denardo A; Gryzik M; Castagna A; Girelli D; Naggi A; Arosio P; Poli M
Biochem Pharmacol; 2020 May; 175():113867. PubMed ID: 32088260
[TBL] [Abstract][Full Text] [Related]
12. Non-Anticoagulant Heparins Are Hepcidin Antagonists for the Treatment of Anemia.
Poli M; Asperti M; Ruzzenenti P; Naggi A; Arosio P
Molecules; 2017 Apr; 22(4):. PubMed ID: 28397746
[TBL] [Abstract][Full Text] [Related]
13. The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys.
Schwoebel F; van Eijk LT; Zboralski D; Sell S; Buchner K; Maasch C; Purschke WG; Humphrey M; Zöllner S; Eulberg D; Morich F; Pickkers P; Klussmann S
Blood; 2013 Mar; 121(12):2311-5. PubMed ID: 23349391
[TBL] [Abstract][Full Text] [Related]
14. Effects of IL-10 on iron metabolism in LPS-induced inflammatory mice via modulating hepcidin expression.
Huang P; Wang J; Lin X; Yang FF; Tan JH
Eur Rev Med Pharmacol Sci; 2017 Aug; 21(15):3469-3475. PubMed ID: 28829493
[TBL] [Abstract][Full Text] [Related]
15. Added value of hepcidin quantification for the diagnosis and follow-up of anemia-related diseases.
Lefebvre T; Lasocki S; Fénéant-Thibault M; Lamy PJ; Cunat S; Ropert-Bouchet M; Aguilar-Martinez P; Lehmann S; Delaby C
Ann Biol Clin (Paris); 2017 Feb; 75(1):9-18. PubMed ID: 28132948
[TBL] [Abstract][Full Text] [Related]
16. Phlebotomies or erythropoietin injections allow mobilization of iron stores in a mouse model mimicking intensive care anemia.
Lasocki S; Millot S; Andrieu V; Lettéron P; Pilard N; Muzeau F; Thibaudeau O; Montravers P; Beaumont C
Crit Care Med; 2008 Aug; 36(8):2388-94. PubMed ID: 18664788
[TBL] [Abstract][Full Text] [Related]
17. Anemia of inflammation: the cytokine-hepcidin link.
Andrews NC
J Clin Invest; 2004 May; 113(9):1251-3. PubMed ID: 15124013
[TBL] [Abstract][Full Text] [Related]
18. S-Propargyl-Cysteine, a Novel Hydrogen Sulfide Donor, Inhibits Inflammatory Hepcidin and Relieves Anemia of Inflammation by Inhibiting IL-6/STAT3 Pathway.
Wang M; Tang W; Xin H; Zhu YZ
PLoS One; 2016; 11(9):e0163289. PubMed ID: 27649298
[TBL] [Abstract][Full Text] [Related]
19. Analysis of IL-22 contribution to hepcidin induction and hypoferremia during the response to LPS in vivo.
Wallace DF; Subramaniam VN
Int Immunol; 2015 Jun; 27(6):281-7. PubMed ID: 25568302
[TBL] [Abstract][Full Text] [Related]
20. The iron-regulatory hormone hepcidin: a possible therapeutic target?
Rochette L; Gudjoncik A; Guenancia C; Zeller M; Cottin Y; Vergely C
Pharmacol Ther; 2015 Feb; 146():35-52. PubMed ID: 25205158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
